{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"26.1","upperLimit":"55.8","value":"38.2"},{"comment":"insufficient number of participants with event to calculate upper limit per K-M methodology","groupId":"OG001","lowerLimit":"43.6","upperLimit":"NA","value":"56.7"},{"comment":"insufficient number of participants with event to calculate upper limit or median per K-M methodology","groupId":"OG002","lowerLimit":"26.2","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"56"},{"groupId":"OG001","value":"112"},{"groupId":"OG002","value":"18"}],"units":"Participants"}],"description":"OS is defined as the time from start of treatment until the time of death from any cause. If no death is recorded the subject will be censored at the time the subject was last known to be alive. Based on Kaplan-Meier Estimates","dispersionType":"95% Confidence Interval","groups":[{"description":"(Pomalidomide + low dose Dexamethasone) in participants with 2 prior lines of therapy with the most recent line of therapy containing lenalidomide. The starting dose level of POM was 4 mg. The starting dose level of Dex was 40 mg/day (≤75 years old) or 20 mg/day (\\> 75 years old).","id":"OG000","title":"Cohort A"},{"description":"(Pomalidomide + Daratumumab + low dose Dexamethasone) in participants with 1 or 2 prior lines of therapy with the most recent line of therapy containing lenalidomide. The starting dose level of POM was 4 mg. The starting dose level of Dex was 40 mg/day (≤75 years old) or 20 mg/day (\\> 75 years old). DARA was administered intravenously (IV) at a starting dose of 16 mg/kg.","id":"OG001","title":"Cohort B"},{"description":"(Pomalidomide + Daratumumab + low dose Dexamethasone) in Japanese participants with 1 or 2 prior lines of therapy with the most recent line of therapy containing lenalidomide. The starting dose level of POM was 4 mg. The starting dose level of Dex was 40 mg/day (≤75 years old) or 20 mg/day (\\> 75 years old). DARA was administered intravenously (IV) at a starting dose of 16 mg/kg.","id":"OG002","title":"Cohort C"}],"paramType":"MEDIAN","populationDescription":"All treated participants","reportingStatus":"POSTED","timeFrame":"From first dose until death due to any cause (Up to 130 months)","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"Months"}